Sacituzumab Govitecan (SG)(Gilead / Immunomedics)은 Urothelial Cancer 표적 ADC로, Urothelial Carcinoma; Muscle-invasive Bladder Cancer 영역에서 개발·상용화 중입니다. 작용기전: targets, signaling pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 44% (ClinicalTrials.gov NCT04916002). PK: t½ 24 h. 차별점: novel treatment options for amyloid removal.
Urothelial Cancer
Urothelial Carcinoma; Muscle-invasive Bladder Cancer
Recruiting
ADCs) have redefined therapeutic paradigms in metastatic breast
deruxtecan, sacituzumab govitecan, datopotamab der
humanized IgG1 and a pan-amyloid reactive peptide, p5R
novel treatment options for amyloid removal
targets, signaling pathway
apoptosis signaling pathways
eGFR, and low
Bypass for Refractory GERD With Predominant Non-Acid Reflux After Single-Anastomosis Duodenojejunal Bypass Diagnosed by Multic
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sacituzumab Govitecan (SG)(Gilead / Immunomedics)은 Urothelial Cancer 표적 ADC로, Urothelial Carcinoma; Muscle-invasive Bladder Cancer 영역에서 개발·상용화 중입니다. 작용기전: targets, signaling pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 44% (ClinicalTrials.gov NCT04916002). PK: t½ 24 h. 차별점: novel treatment options for amyloid removal.
Urothelial Cancer
Urothelial Carcinoma; Muscle-invasive Bladder Cancer
Recruiting
ADCs) have redefined therapeutic paradigms in metastatic breast
deruxtecan, sacituzumab govitecan, datopotamab der
humanized IgG1 and a pan-amyloid reactive peptide, p5R
novel treatment options for amyloid removal
targets, signaling pathway
apoptosis signaling pathways
eGFR, and low
Bypass for Refractory GERD With Predominant Non-Acid Reflux After Single-Anastomosis Duodenojejunal Bypass Diagnosed by Multic
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.